Literature DB >> 26743473

Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.

Ozgur Mete1, Karen Gomez-Hernandez2, Walter Kucharczyk3, Rowena Ridout2, Gelareh Zadeh4, Fred Gentili4, Shereen Ezzat2, Sylvia L Asa1.   

Abstract

Originally classified as a variant of silent corticotroph adenoma, silent subtype 3 adenomas are a distinct histologic variant of pituitary adenoma of unknown cytogenesis. We reviewed the clinical, biochemical, radiological, immunohistochemical and ultrastructural features of 31 silent subtype 3 adenomas to clarify their cellular origin. Among 25 with clinical and/or radiological data, all were macroadenomas; there was cavernous sinus invasion in 30% of cases and involvement of the clivus in 17% of cases. Almost 90% of patients were symptomatic; 67% had mass effect symptoms, 37% were hypogonadal and 8% had secondary adrenal insufficiency. Significant hormonal excess in 29% of cases included hyperthyroidism in 17%, acromegaly in 8% and hyperprolactinemia above 150 μg/l in 4%. Two individuals with hyperprolactinemia who were younger than 30 years had multiple endocrine neoplasia type 1. Immunohistochemically, all 31 tumors were diffusely positive for the pituitary lineage-specific transcription factor Pit-1. Although three only expressed Pit-1, others revealed variable positivity for one or more hormones of Pit-1 cell lineage (growth hormone, prolactin, thyroid-stimulating hormone), as well as alpha-subunit and estrogen receptor. Most tumors exhibited perinuclear reactivity for keratins with the CAM5.2 antibody; scattered fibrous bodies were noted in five (16%) tumors. The mean MIB-1 labeling index was 4% (range, 1-9%). Fourteen cases examined by electron microscopy were composed of a monomorphous population of large polygonal or elongated cells with nuclear spheridia. Sixty-five percent of patients had residual disease after surgery; after a mean follow-up of 48.4 months (median 41.5; range=2-171) disease progression was documented in 53% of those cases. These data identify silent subtype 3 adenomas as aggressive monomorphous plurihormonal adenomas of Pit-1 lineage that may be associated with hyperthyroidism, acromegaly or galactorrhea and amenorrhea. Our findings argue against the use of the nomenclature 'silent' for these tumors. To better reflect the characteristics of these tumors, we propose that they be classified as 'poorly differentiated Pit-1 lineage adenomas'.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26743473     DOI: 10.1038/modpathol.2015.151

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  22 in total

Review 1.  The pathogenesis of pituitary tumors.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

Review 2.  Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.

Authors:  Karen Gomez-Hernandez; Shereen Ezzat; Sylvia L Asa; Özgür Mete
Journal:  Turk Patoloji Derg       Date:  2015

3.  The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.

Authors:  Hiroshi Nishioka; Naoko Inoshita; Ozgur Mete; Sylvia L Asa; Kyohei Hayashi; Akira Takeshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Yasuhiro Takeuchi; Shozo Yamada
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

4.  Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics.

Authors:  James A Balogun; Eric Monsalves; Kyle Juraschka; Kashif Parvez; Walter Kucharczyk; Ozgur Mete; Fred Gentili; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

5.  Clinically silent corticotroph tumors of the pituitary gland.

Authors:  B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young
Journal:  Neurosurgery       Date:  2000-09       Impact factor: 4.654

6.  Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience.

Authors:  D Erickson; B Scheithauer; J Atkinson; E Horvath; K Kovacs; R V Lloyd; W F Young
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-18       Impact factor: 3.478

7.  Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form.

Authors:  Abdulkader Obari; Toshiaki Sano; Kenichi Ohyama; Eiji Kudo; Zhi Rong Qian; Akiko Yoneda; Nasim Rayhan; Muhammad Mustafizur Rahman; Shozo Yamada
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

8.  Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism.

Authors:  Bernardo Dias Pereira; Luísa Raimundo; Ozgur Mete; Ana Oliveira; Jorge Portugal; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

Review 9.  Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas.

Authors:  O M Dekkers; A M Pereira; J A Romijn
Journal:  J Clin Endocrinol Metab       Date:  2008-08-05       Impact factor: 5.958

10.  A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas.

Authors:  Shozo Yamada; Kenichi Ohyama; Manabu Taguchi; Akira Takeshita; Koji Morita; Koji Takano; Toshiaki Sano
Journal:  Neurosurgery       Date:  2007-09       Impact factor: 4.654

View more
  34 in total

1.  Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.

Authors:  Ozgur Mete; Omalkhaire M Alshaikh; Amber Cintosun; Shereen Ezzat; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

Review 2.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 3.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes.

Authors:  Yuichi Nagata; Naoko Inoshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Hiroshi Nishioka; Takeo Iwata; Katsuhiko Yoshimoto; Shozo Yamada
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

Review 5.  Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).

Authors:  Nèle Lenders; Ann McCormack
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 6.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

7.  Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Elena Varlamov; Chris G Yedinak; Justin S Cetas; Shirley McCartney; Aclan Dogan; Maria Fleseriu
Journal:  Endocrine       Date:  2017-10-17       Impact factor: 3.633

8.  Effects of pterostilbene on treating hyperprolactinemia and related mechanisms.

Authors:  Haoru Zhang; Changhua Wang; Xiaokun Li; Yong Zhang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

9.  Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism.

Authors:  Bernardo Dias Pereira; Luísa Raimundo; Ozgur Mete; Ana Oliveira; Jorge Portugal; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

Review 10.  Immunohistochemical Biomarkers in Pituitary Pathology.

Authors:  Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.